INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Condition: Advanced Malignancies
Estimated Enrollment: 10
Gender: All
Min Age: 18 Years
Age Group: Adult, Older Adult
Current Status: Active, not recruiting
Study Results: No Results Available
Outcome Measures: Phase 1: Participants With Treatment-Emergent Adverse Events (TEAEs) [Safety and Tolerability], Phase 2: Objective response rate (ORR) based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, Phase 2: Complete response rate (CRR) based on RECIST v1.1, Phase 1: ORR based on RECIST v1.1 and mRECIST
Interventions: INCAGN01876, Epacadostat
Phase:
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,
Primary Completion Date: March 2020
Completion Date: May 2020
Last Posted Date: May 7, 2019
Location: The Angeles Clinic and Research Institute, Los Angeles, California, United States
Website Link: https://ClinicalTrials.gov/show/NCT03277352